X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with Abbott India - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs ABBOTT INDIA - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA ABBOTT INDIA ASTRAZENECA PHARMA/
ABBOTT INDIA
 
P/E (TTM) x 119.5 41.6 287.3% View Chart
P/BV x 17.0 10.4 163.8% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 ASTRAZENECA PHARMA   ABBOTT INDIA
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
ABBOTT INDIA
Mar-16
ASTRAZENECA PHARMA/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs1,2856,015 21.4%   
Low Rs6343,707 17.1%   
Sales per share (Unadj.) Rs189.61,236.9 15.3%  
Earnings per share (Unadj.) Rs-0.2122.2 -0.2%  
Cash flow per share (Unadj.) Rs3.8129.0 3.0%  
Dividends per share (Unadj.) Rs035.00 0.0%  
Dividend yield (eoy) %00.7 0.0%  
Book value per share (Unadj.) Rs68.6521.2 13.2%  
Shares outstanding (eoy) m25.0021.25 117.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.13.9 128.8%   
Avg P/E ratio x-4,712.739.8 -11,845.1%  
P/CF ratio (eoy) x249.637.7 662.2%  
Price / Book Value ratio x14.09.3 149.9%  
Dividend payout %028.6 0.0%   
Avg Mkt Cap Rs m23,988103,296 23.2%   
No. of employees `0001.63.0 52.7%   
Total wages/salary Rs m1,6053,370 47.6%   
Avg. sales/employee Rs Th3,040.28,891.8 34.2%   
Avg. wages/employee Rs Th1,029.21,140.0 90.3%   
Avg. net profit/employee Rs Th-3.3878.3 -0.4%   
INCOME DATA
Net Sales Rs m4,74026,284 18.0%  
Other income Rs m92504 18.3%   
Total revenues Rs m4,83226,789 18.0%   
Gross profit Rs m-1303,665 -3.5%  
Depreciation Rs m101144 70.1%   
Interest Rs m08 0.0%   
Profit before tax Rs m-1394,017 -3.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1390-   
Tax Rs m51,421 0.4%   
Profit after tax Rs m-52,596 -0.2%  
Gross profit margin %-2.713.9 -19.6%  
Effective tax rate %-3.735.4 -10.4%   
Net profit margin %-0.19.9 -1.1%  
BALANCE SHEET DATA
Current assets Rs m2,72614,446 18.9%   
Current liabilities Rs m2,4354,725 51.5%   
Net working cap to sales %6.137.0 16.6%  
Current ratio x1.13.1 36.6%  
Inventory Days Days7451 143.5%  
Debtors Days Days4120 208.4%  
Net fixed assets Rs m1,0351,113 93.0%   
Share capital Rs m50213 23.5%   
"Free" reserves Rs m94210,808 8.7%   
Net worth Rs m1,71611,076 15.5%   
Long term debt Rs m00-   
Total assets Rs m4,15616,241 25.6%  
Interest coverage xNM497.0-  
Debt to equity ratio x00-  
Sales to assets ratio x1.11.6 70.5%   
Return on assets %-0.116.0 -0.8%  
Return on equity %-0.323.4 -1.3%  
Return on capital %036.3 0.0%  
Exports to sales %5.70.6 927.2%   
Imports to sales %6.512.6 51.1%   
Exports (fob) Rs m270162 167.2%   
Imports (cif) Rs m3063,322 9.2%   
Fx inflow Rs m375268 139.8%   
Fx outflow Rs m4703,927 12.0%   
Net fx Rs m-96-3,659 2.6%   
CASH FLOW
From Operations Rs m-82,514 -0.3%  
From Investments Rs m-146-800 18.2%  
From Financial Activity Rs m862-803 -107.4%  
Net Cashflow Rs m709912 77.7%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 75.0 100.0%  
Indian inst/Mut Fund % 0.3 7.9 3.8%  
FIIs % 15.7 0.1 15,700.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 17.1 53.2%  
Shareholders   12,856 18,270 70.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   CADILA HEALTHCARE  TTK HEALTHCARE  SHASUN PHARMA  DISHMAN PHARMA  J.B.CHEMICALS  

Compare ASTRAZENECA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day in Red; Realty Stocks Top Losers(Closing)

After opening the day in green, share markets in India witnessed volatile trading activity throughout the day and ended the day on a dull note.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Is it Wise to Ignore Bitcoins?(The 5 Minute Wrapup)

Jan 4, 2018

While investing in bitcoins, it would make sense to treat it as another asset class and decide accordingly.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Jan 16, 2018 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS